Xenikos Set To Start Phase III For Acute GVHD Drug
Executive Summary
The Dutch biotech's CEO tells Scrip that one-week treatment with T-Guard could change the paradigm for tackling steroid-refractory graft-versus-host disease.
Topics
- Subjects
- Clinical Trials
- Companies
- FDA
- Therapy Areas
- Immune Disorders
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125371
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC125371
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.